Today, Ian Ainsworth and Gavin Graham commented about whether CSE-T, CJT-T, ESV-N, 005930-KRX, PG-N, CHL-N, BCS-N, CPG-T, AGT-T, AX.UN-T, COS-T, EC-N, EMC-N, LYG-N, CSCO-Q, PRE-T, BIP.UN-T, IFC-T, MJN-N, S-T, GE-N, UL-N, GM-N, AAPL-Q, CVE-T, RMG-LSE, TD-T, AAPL-Q, INTC-Q, BB-T, AMT-N, SBUX-Q, GLW-N, QCOM-Q, ILMN-Q, VAR-N, PANW-N, GOOG-Q, META-Q, ORCL-N, GILD-Q, EL-N, VMW-N, CCT-T, SVC-T, GIB.A-T are stocks to buy or sell.
Great company, strong position in databases. Companies find it hard to move away from them. The problem is that the DB business is fairly mature. Oracle is slow to adapt to the cloud, however they are also unsure how to deal with ‘Big Data’. Others are finding that the world is changing very rapidly. A solid company but the transition is going to start to eat into their growth. This does not qualify according to his growth criteria.
Not positioned for mobile because their chips use too much energy. They are moving to better chips to compete with ARM. There is this big battle going on and it will pressure prices for a while. Their margins will come under pressure. They can probably continue with their dividend but growth will come under pressure.
Economy. Does not expect the US government will proceed with tapering. There may be some evidence of weakness of US numbers in the last few months and the feds credibility was severely damaged. If they weren’t going to do. Tapering, why did they freak out the market and push up long-term bond rates by 1%. It may well be that we are seeing the feds starting to lose, at least, in the long end of the bond market. People are now going to look at anything they say with a very large grain of salt. Tapering could very well be delayed until this time next year. The Fed essentially goes on hold usually after August or September when there is an election year. The new Fed chairperson has about 6 months. Margin debts are back to record highs. This is all looking dangerously close to at least an interim peak for the S&P 500.
Likes their technology and products. When he models out the prospects for their new HEP C drug the numbers don’t work. Thinks the new product is already built in.